Abstract
The synthesis of a novel gut selective MTP inhibitor, 5-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-1H-indole-2-carboxylic acid benzylmethyl carbamoylamide (dirlotapide), and its in vitro and in vivo profile are described. Dirlotapide (3) demonstrated excellent potency against MTP enzyme in HepG2 cells and canine hepatocytes. This novel MTP inhibitor also showed excellent efficacy when tested in a canine food intake model.
MeSH terms
-
Animals
-
Carbamates / chemical synthesis*
-
Carbamates / chemistry
-
Carbamates / pharmacology
-
Carboxylic Acids / chemical synthesis*
-
Carboxylic Acids / chemistry*
-
Carboxylic Acids / pharmacology
-
Carrier Proteins / antagonists & inhibitors*
-
Chemistry, Pharmaceutical / methods*
-
Dogs
-
Drug Design
-
Drug Evaluation, Preclinical
-
Humans
-
Hydrogen-Ion Concentration
-
In Vitro Techniques
-
Indoles / chemical synthesis*
-
Indoles / chemistry
-
Indoles / pharmacology
-
Inhibitory Concentration 50
-
Models, Chemical
-
Molecular Conformation
-
Obesity / drug therapy*
-
Rats
Substances
-
Carbamates
-
Carboxylic Acids
-
Carrier Proteins
-
Indoles
-
microsomal triglyceride transfer protein
-
dirlotapide